

## Nova Scotia Provincial Pharmacare Programs

### Request for Coverage of Restricted Systemic Agents for Atopic Dermatitis

#### PATIENT INFORMATION

PATIENT SURNAME	PATIENT GIVEN NAME	HEALTH CARD NUMBER	DATE OF BIRTH
-----------------	--------------------	--------------------	---------------

PATIENT ADDRESS

#### REQUEST FOR INITIAL COVERAGE

**Requested Agent:**  
 Abrocitinib     Dupilumab

**Diagnosis:**  
 For the treatment of moderate to severe atopic dermatitis in patients 12 years of age and older, who meet **ALL** of the following criteria:

1.  Baseline Physician Global Assessment score  $\geq 3$  and Eczema Area and Severity Index (EASI) score of  $\geq 7.1$   
 Baseline Physician Global Assessment Score: \_\_\_\_\_ Date: \_\_\_\_\_ EASI Score: \_\_\_\_\_ Date: \_\_\_\_\_

**Patient's Past Medication History:**

2.  Had an adequate trial (with a documented refractory disease), or were intolerant (with documented intolerance), or are ineligible for each of the following therapies (**Please provide details below**):

- Maximally tolerated medical topical therapies for AD combined with phototherapy (where available), **and**;
- Maximally tolerated medical topical therapies for AD combined with at least 1 of the 4 systemic immunomodulators (methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine).

3. Agents tried: Length of therapy, outcome (i.e., not effective or details of intolerance); if contraindicated (provide details)

<input type="checkbox"/> Medical topical therapies	_____
<input type="checkbox"/> Phototherapy	_____
<input type="checkbox"/> Methotrexate	_____
<input type="checkbox"/> Cyclosporine	_____
<input type="checkbox"/> Mycophenolate mofetil	_____
<input type="checkbox"/> Azathioprine	_____

#### REQUEST FOR COVERAGE RENEWAL

**Initial Renewal request:**  
 Beneficial clinical effect, defined as a 75% or greater improvement from baseline in the EASI score (EASI-75) six months after treatment initiation.

Eczema Area and Severity Index score: \_\_\_\_\_ Date: \_\_\_\_\_

**Subsequent Renewal Requests:**  
 Maintenance of EASI-75 response from baseline

Eczema Area and Severity Index score: \_\_\_\_\_ Date: \_\_\_\_\_

PRESCRIBER NAME & ADDRESS:   	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%; border-bottom: 1px solid black; text-align: center;">LICENCE #</td> <td style="width: 33%; border-bottom: 1px solid black; text-align: center;">PRESCRIBER SIGNATURE</td> <td style="width: 33%; border-bottom: 1px solid black; text-align: center;">DATE</td> </tr> </table>	LICENCE #	PRESCRIBER SIGNATURE	DATE
LICENCE #	PRESCRIBER SIGNATURE	DATE		

**If you need assistance, please contact the Pharmacare Office at (902) 496-7001 or 1-800-305-5026**

**Please Return Form To:** Nova Scotia Pharmacare Programs  
 P.O. Box 500, Halifax, NS B3J 2S1, Fax: (902) 496-4440

11/2023

